ArticleCell communication and signaling : CCS2026
Signaling pathways regulating VDAC1 overexpression associated with apoptosis, pyroptosis, and ferroptosis.
Article in Cell communication and signaling : CCS, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Disrupting VDAC1-tubulin interaction uncovers crosstalk between mitochondrial and microtubule functions with implication to cancer therapy.Cellular and molecular life sciences : CMLS · 2026Article
- Targeting VDAC1 to protect against mitochondria-linked cell death pathways: apoptosis, pyroptosis, ferroptosis, and associated diseases.Apoptosis : an international journal on programmed cell death · 2026Article
- VDAC1-interacting proteins: binding site mapping and their derived peptides induce apoptosis and multifaceted cellular effects.Apoptosis : an international journal on programmed cell death · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Mitochondrial VDAC1 is a multi-functional protein that acts as a convergence point for various cell survival and death signals. Under stress and pathological conditions, VDAC1 is overexpressed. This leads to its oligomerization, which forms a large channel allowing pro-apoptotic proteins release and subsequent apoptosis. Here, we studied the signaling pathways regulating VDAC1 overexpression. We show that various agents, inducing programmed cell death (PCD), including apoptosis, ferroptosis, or pyroptosis, also increased VDAC1 expression levels and its oligomerization. Activation of p38-MAPK, c-Jun, N-terminal kinase (JNK), and calmodulin kinase-II signaling pathways by PCD inducers resulted in phosphorylation of the transcription factors (TFs) c-Jun, c-Fos, and ATF-1, and enhanced VDAC1 expression. Consequently, inhibiting these pathways using specific inhibitors decreased VDAC1 expression at the protein and mRNA levels and PCD. Similar results were obtained using a reporter gene approach—the VDAC1-promoter-luciferase construct—in which the activation of apoptosis resulted in the transcription of luciferase that was reduced by signaling pathway inhibitors. These results suggest that the VDAC1 promoter is regulated by the p38-MAPK, JNK, and calmodulin-dependent kinase-II signaling pathways via activation of the TFs c-Jun, c-Fos, and ATF-1 and required Ca2+. These three TFs, upon their activation by cisplatin, bind to the VDAC1 promoter, as demonstrated by a ChIP assay. Thus, VDAC1 promoter regulation represents a potential therapeutic for targeting diseases associated with VDAC1 overexpression.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.